The government has approved the rules and criteria for forming a list of strategically important medicines.

Translation. Region: Russian Federation –

Source: Government of the Russian Federation – Government of the Russian Federation –

An important disclaimer is at the bottom of this article.

Document

Resolution of March 17, 2026 No. 277

Comment

From Mikhail Mishustin's opening remarks at the operational meeting with deputy prime ministers, March 24, 2026

Russia will develop a list of strategically important medications that meet the priority needs of the healthcare system for the prevention and treatment of diseases. Their full production cycle must be ensured within the country. The rules and criteria for compiling the list were approved by a decree signed by Prime Minister Mikhail Mishustin. This decision will increase the country's pharmaceutical independence and maintain a stable supply of essential medications to clinics and hospitals.

The list will include vital and essential medications, vaccines included in the national calendar of preventive vaccinations and the calendar of vaccinations for epidemic indications, blood products, blood substitutes, infusion solutions, narcotic analgesics, medications for the treatment of especially dangerous infections, socially significant diseases, and diseases that pose a danger to others.

The production of such drugs will be organized with state support. Furthermore, drugs included in the list will be given priority in government procurement.

"We hope this will reduce the pharmaceutical industry's dependence on foreign suppliers and, overall, contribute to achieving the national goal of preserving the population, improving health and well-being, and supporting families," Mikhail Mishustin noted at a meeting with deputy prime ministers on March 24.

The list will be compiled by a special interdepartmental commission, which will include representatives from the Ministry of Health, the Ministry of Industry and Trade, the Ministry of Finance, the Federal Medical and Biological Agency, the Ministry of Economic Development, the Federal Antimonopoly Service, Roszdravnadzor, and Rospotrebnadzor.

The work is being carried out within the framework of the implementation of the Strategy for the Development of the Pharmaceutical Industry until 2030.

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.